Genfit adds $20M as Ipsen records strong sales for liver drug
Source: SeekingAlpha
2026-02-12 13:52:01 ET
More on Genfit, Ipsen S.A.
- Ipsen S.A. (IPSEY) Q4 2025 Earnings Call Transcript
- Ipsen S.A. 2025 Q4 - Results - Earnings Call Presentation
- Ipsen S.A. (IPSEY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Ipsen S.A. Non-GAAP EPS of €12.09, revenue of €3.68B; sets full-year 2026 guidance and mid-term outlook
- Ipsen rises on FDA breakthrough therapy status for blood cancer therapy
Read the full article on Seeking Alpha
For further details see:
Genfit adds $20M as Ipsen records strong sales for liver drug
Genfit ADR
NASDAQ: GNFTY
GNFTY Trading
-5.63% G/L:
$8.72 Last:
2,203 Volume:
$9.10 Open:
GNFTY Latest News
GNFTY Stock Data
$370,971,693
47,631,365
N/A
9
N/A
Biotechnology & Life Sciences
Healthcare
FR
Loos
